On May 14, 2018, Eli Lilly announced an agreement to acquire AurKa Pharma, a company established by TVM Capital Life Science to develop an oncology compound, in a deal worth up to $575 million. AurKa Pharma is developing AK-01, an Aurora kinase A inhibitor that was originally discovered by LillyOriginal Article
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.